NeuroVive Decides on a Rights Issue for Continued Drug Development - Seite 2

Background and motive

NeuroVive's project portfolio

The Company's project portfolio consists of two projects in clinical development phase: NeuroSTAT for traumatic brain injury (TBI) and KL1333 for genetic mitochondrial diseases. The portfolio contains two additional projects for genetic mitochondrial diseases (NVP015 and NVP025), two projects for the metabolic disease NASH (NV556 and NVP022), and NVP024, a project for liver cancer (HCC). By 2018, the Company intends to initiate a Phase II clinical study of NeuroSTAT and a Phase I clinical study of KL1333.

Milestones in 2017

• In licensing of Yungjin Pharm's drug candidate KL1333 for which a Phase I clinical study was started by Yungjin Pharm in Korea in June 2017.
• Orphan drug designation for KL1333 in Europe.
• Positive results from the Phase II study of NeuroSTAT, CHIC, conducted at Rigshospitalet in Copenhagen.
• Confirming the brain-protective effects of NeuroSTAT after trauma in a translational pre-clinical effect study at the University of Pennsylvania.
• Initiation of NV556 project outlicensing activities.
• Presentation of positive preclinical data in projects NV556 and NVP022 at international scientific congresses.
• Research grant from VINNOVA for project NVP015.
• Lead candidate for continued development selected for NVP015 project and preclinical development initiated.
• Collaboration agreement with Karolinska Institutet on myopathy and NVP025 project.
• Presentation of positive preclinical data in NVP024 project at international scientific congresses.
• Research grant from the Swedish Foundation for Strategic Research for NVP024 project (in collaboration with Lund University).

Goals for 2018

• Results from the clinical Phase I study of KL1333 in Korea.
• Start of the next clinical Phase I study of KL1333 in Europe and / or the United States.
• Presentation of complete results from the Phase II study of NeuroSTAT, CHIC.
• Engage partners and/or receive additional non-diluting funding for NeuroSTAT's clinical Phase II efficacy study.
• Launch of clinical Phase II efficacy study of NeuroSTAT.
• NV556 project outlicensing.
• Results from NVP015 studies at the Children's Hospital of Philadelphia (CHOP).
• Evaluation of substances and selection of lead candidate in NVP025 project.
• Evaluation of substances and selection of lead candidate in NVP022 project.
• Presentation of further experimental studies in NVP024 project, as well as preliminary results from Industrial PhD student collaboration with Lund University.

Motive for the Rights issue